Yantai Dongcheng Biochemicals News

Dongcheng Pharmaceutical (002675): The nuclear drug product pipeline continues to be enriched, opening up room for long-term imagination

Huayuan SecuritiesNov 21, 2024 00:00

Dongcheng Pharmaceutical (002675): The API business is under short-term pressure, and the layout of nuclear drug pipelines is rich

Debang SecuritiesSep 26, 2024 19:16

Dongcheng Pharmaceutical (002675): Revenue improved month-on-month in the second quarter, and the nuclear drug pipeline is expected to be reaped

Sep 6, 2024 13:16

Dongcheng Pharmaceutical (002675): Nuclear drug business stabilizes, revenue from heparin APIs declines

guolianSep 3, 2024 16:36

Dongcheng Pharmaceutical (002675): A leader in the nuclear medicine industry, innovative assets lead value reshaping

May 28, 2024 00:00

Dongcheng Pharmaceutical (002675) Company Brief Review Report: Multiple Factors Influence Short-Term Performance, Steady Progress in Innovative Nuclear Drug Research and Development

May 7, 2024 00:00

Dongcheng Pharmaceutical (002675): Heparin API cycle fluctuations and collection affect current performance, nuclear drug innovation and upgrading can be expected in the future

May 6, 2024 18:06

Dongcheng Pharmaceutical (002675): Performance fluctuations due to heparin APIs, innovative nuclear drugs are expected to reap

May 5, 2024 16:41

Dongcheng Pharmaceutical (002675): Heparin business disrupts performance testing and has a rich layout of nuclear drugs

May 5, 2024 00:00

Dongcheng Pharmaceutical (002675): Heparin volume and price has bottomed out and is expected to resume its leading position in the nuclear drug layout in the country

May 4, 2024 00:00

Dongcheng Pharmaceutical (002675): Short-term pressure on performance due to heparin APIs, 2024 ushered in a nuclear drug pipeline implementation period

May 1, 2024 07:16

Dongcheng Pharmaceutical (002675): Short-term pressure on performance due to heparin APIs, 2024 ushered in a nuclear drug pipeline implementation period

Apr 28, 2024 21:01

Research Report Nuggets | Open Source Securities: Maintaining Dongcheng Pharmaceutical's “Buy” Rating, Relevant Products Are Expected to Gradually Implement Subsequent Relevant Products

Gelonghui FinanceNov 17, 2023 17:23

Dongcheng Pharmaceutical (002675): Short-term performance under pressure, innovative nuclear drug research and development continues to advance

Nov 16, 2023 00:00

Dongcheng Pharmaceutical (002675): Increase upstream nuclide supply layout and continue to improve the nuclear drug ecosystem

Nov 15, 2023 08:02

Dongcheng Pharmaceutical (002675): Short-term performance under pressure, rapid clinical progress of nuclear drug products

Nov 8, 2023 00:00

Dongcheng Pharmaceutical (002675): Nuclear drug business is growing steadily, and research and development of innovative diagnostic nuclear drugs is progressing smoothly

China International Capital CorporationOct 30, 2023 00:00

Dongcheng Pharmaceutical (002675): Under pressure on Q3 performance, it is recommended to focus on the value of nuclear drug innovation drug pipelines

Debon SecuritiesOct 29, 2023 00:00

Dongcheng Pharmaceutical (002675) 2023 Third Quarter Report Review: Fluctuations in APIs, Short-term performance under pressure, and continuous improvement of the layout of the entire nuclear drug industry chain

Western SecuritiesOct 26, 2023 00:00

Dongcheng Pharmaceutical (002675): Steady growth in performance to build a nuclear pharmaceutical ecosystem network throughout the industry chain

天風證券Sep 10, 2023 00:00